Corgi ONTO 2x Daily ETF ONTX
As ofNov 20, 2026, 1:43 PM EST
- YTD
- -81.61%
- 1 year
- -81.61%
5D -0.70 (-9.46%)
- Assets
- $693.63K
- Expense ratio
- 0.45%
- NAV
- 6.43
- Holdings
- 1
- Asset class
- Leveraged/Inverse
- Issuer
- Corgi Funds
- Inception
- Jun 24, 2026
- YTD return
- -81.61%
- 1-year return
- -81.61%
- Volume
- 11.76K
- Avg volume
- 14.96K
- Open
- 4.75
- Previous close
- 6.38
- Day's range
- 4.66 – 4.75
- 52-week range
- 4.19 – 43.14
- 50-day average
- 0.815224
- 200-day average
- 0.783364
About Corgi ONTO 2x Daily ETF
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- onconova.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ONTX — it syncs with the Stock Master app.
